Insulin use, adipokine profiles and breast cancer prognosis

详细信息    查看全文

• 作者：Zachary A.P. Wintrob^a ; Jeffrey P. Hammel^b ; Thaer Khoury^c ; George K. Nimako^a ; Hsin-Wei Fu^a ; Zahra S. Fayazi^a ; Dan P. Gaile^d ; Alan Forrest^e ; Alice C. Ceacareanu^a ; ^f ; ^{ACC36@BUFFALO.EDU}
• 关键词：Insulin ; Secretagogue ; Breast cancer prognosis ; Breast cancer outcomes ; Adipokine
• 刊名：Cytokine
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：89
• 期：Complete
• 页码：45-61
• 全文大小：2596 K
• 卷排序：89

文摘

Insulin and insulin secretagogue users have poorer breast cancer (BC) outcomes. Estrogen receptor negative BC occurs more among insulin and secretagogues users. Insulin users have lower baseline C-peptide and elevated leptin, IL-6, TNF-α and CRP. C-peptide is inversely correlated with IL-1β and IL-1Ra among insulin users. IL-1β and adiponectin levels are directly correlated in insulin users only.